Raj Chovatiya, MD, PhD, assistant professor of dermatology and Medical Director, Center for Eczema and Itch and Medical Director, Clinical Trials Unit at the Northwestern University Feinberg School of Medicine in Chicago, Illinois, shares highlights from his upcoming presentations at Fall Clinical in Las Vegas, Nevada, October 20-23, 2022.
My name is Dr. Raj Chovatiya, and I'm assistant professor of dermatology, Director, Center for Eczema and Itch and Medical Director, Clinical Trials Unit at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.
I'm also an editorial advisory board member for Dermatology Times, and I'm really excited to talk about some of the new topics I'm going to be discussing the upcoming fall clinical conference in Las Vegas this October. In one of my talks, I'll be presenting a whirlwind tour of topical steroid therapy for psoriasis. Now, in particular, I'm going to focus on the rationale of why we treat psoriasis with topical steroids as first line therapy, the advantages of combination therapy, and then a little bit of new discussion on recent evolution in the space in terms of topical formulation and drug delivery.
In addition, one of my favorite things to talk about, is to delve into topical medication adherence and hopefully enlightened listeners as to why adherence is oftentimes even more important concept and advocacy itself. Additionally, I'm going to be talking about early dermatology practice pearls in atopic dermatitis with a targeted focus on helpful information for those who are really starting out in practice. Atopic dermatitis is one of the most common conditions we see in dermatology. If you're going to be in practice, you're going to see it, but it can be a challenging disease. To diagnose and manage that, let's talk I'm going to really rewind the script and take it back to basics and talk a little bit about the terminology confusion that exists with atopic dermatitis and eczema. What are the differences? When do they mean the same thing, how atopic dermatitis is diagnosed by the book and how this can actually be limited sometimes, and then kind of revising our view of what makes classic atopic dermatitis and finally, what else you should be thinking about when it comes to that differential diagnosis with dermatitis.
I'm also going to be participating in a panel discussion about early career dermatology tips and tricks with several other young dermatologists in focus on many of the practical aspects of practice, like work life balance, financial planning, and even time management. I'm also going to be participating in an exciting panel discussion on key issues and inflammatory disease management in patients with skin color. This includes Hydra adenitis support Teva, psoriasis, atopic dermatitis, our focus is going to be reviewed some of the unique elements of disease presentation and quality life burden that can make disease management particularly challenging across diverse skin types. Finally, I'm going to have the opportunity to review some of the key data about the treatment of mild to moderate atopic dermatitis with the topical Jak inhibitor: My focus here is going to be talking about the improvement and immense disease burden that we associate with atopic dermatitis. And in particular, we're going to address itch and skin lesions that are associated with the disease. Look forward to seeing you there.